Metastasis-directed therapy shows benefit for HNSCC

  • Beckham TH & al.
  • Br J Cancer
  • 25 Oct 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Metastasis-directed therapy (MDT) is associated with improved OS of patients with head and neck squamous cell carcinoma (HNSCC) with limited metastatic disease burden.

Why this matters

  • This study adds to mounting evidence for a beneficial role of local therapy strategies in patients with limited metastatic burden.

Key results

  • 5-year OS was 9% in the entire cohort (35% in patients with a single metastasis, 4% in patients with multiple metastases).
  • MDT was associated with improved OS (HR, 0.36; P=.006) in multivariate analysis.
  • Oral cavity primary (HR, 2.22; P=.015) and sinonasal primary (HR, 4.88; P=.037) were associated with reduced OS in multivariate analysis.
  • Estimated median metastasis-free survival and 5-year OS after MDT were 26.4 months and 31%, respectively.

Study design

  • 186 patients with HNSCC and metastatic disease, 16.1% who underwent MDT (14% surgery, 1.6% radiation therapy, 0.5% radiofrequency ablation), were analyzed for outcomes and associated factors.
  • Funding: NIH/National Cancer Institute.

Limitations

  • Retrospective study with patient and treatment heterogeneity.